Dose Escalation for Oligometastatic Disease: Is More Better?

Stereotactic body radiation therapy for spine and non-spine bone metastases. GETUG (french society of urological radiation oncologists) recommendations using a national two-round modified Delphi survey

“…27 Although exciting, these results should not yet be broadly applied as they were achieved in a highly selected population treated in a center of excellence with limited follow-up and as ultrahigh-dose single-fraction SBRT might cause serious longterm side effects. 28 In order to allow for the generation of a sharp dose gradient, GETUG experts agreed that the prescription dose should be prescribed on the isodose line that encompasses ≥95% of PTV and that the dose distribution inside PTV should be kept heterogeneous beyond 107% and up to 140% of the prescription dose. As an option, a simultaneous integrated boost technique can be used to keep the maximal dose inside GTV.…”

“… [27] Although exciting, these results should not yet be broadly applied as they were achieved in a highly selected population treated in a center of excellence with limited follow-up and as ultrahigh-dose single-fraction SBRT might cause serious long-term side effects. [28] .…”